H1 2025 Recap: Key Signals from the Tech+Bio Frontier

A high-signal summary of some of the most important moves and trends shaping biotech and tech-enabled life sciences in the first half of 2025

Hi there! While hiding from the 38 °C heat under my airco—my best friend for this summer—I decided that it is the right time to reflect on an incredibly eventful but also a bit of a rollercoaster tech+bio space in the first half of 2025.

In this issue: Financial Climate & Deal-Making Power Shift — Gene Therapies are a Mixed Bag — AI Drug Discovery is Recalibrating — Big Data & Data Infrastructures Define Leaders — a Year of Next Generation Sequencing — Away from Animal Models — Brain-Computer Interfaces are Having Momentum

Before we dive in, I will be visiting the Aging Research & Drug Discovery Meeting - ARDD 2025, so let’s meet sometime between August 25-29 in Copenhagen!

---

Image credit: iStock, AWelshLad

Financial Climate & Deal-Making Power Shift

So, first things first, what does the market and venture capital space look like now when we enter H2?

This article is for paid subscribers of BiopharmaTrend Pro membership.

---